N-(2-羧基-3-苯基丙酰基)-L-亮氨酸 | 209127-97-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-(2-羧基-3-苯基丙酰基)-L-亮氨酸
• 英文名称: N-<(RS)-2-carboxy-3-phenylpropanoyl>-L-leucine
• 英文别名: (2S)-2-(2-Carboxy-3-phenylpropanamido)-4-methylpentanoic acid；(2S)-2-[(2-carboxy-3-phenylpropanoyl)amino]-4-methylpentanoic acid
• CAS: 209127-97-9
• 化学式: C₁₆H₂₁NO₅
• 分子量: 307.346
• InChiKey: REOCNKZXONOGGX-ABLWVSNPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  22
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  104
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  N-[(RS)-2-carbethoxy-3-phenylpropanoyl]-L-leucine 在 sodium hydroxide 作用下， 以 丙酮 为溶剂， 以95%的产率得到N-(2-羧基-3-苯基丙酰基)-L-亮氨酸
  参考文献：
  名称：

  脑脑啡肽酶的新型羧烷基抑制剂：合成，生物活性和止痛特性。

  摘要：

  合成了衍生自Phe-Leu和Phe-Ala的新羧烷基化合物，并将其作为“脑啡肽酶”的抑制剂进行检查，这是一种从小鼠纹状体膜上裂解脑啡肽的Gly3-Phe4键的金属内肽酶。这些羧烷基化合物对脑脑啡肽酶和血管紧张素转化酶（ACE）催化位点的差异识别会导致脑啡肽降解酶的有效抑制剂（KI约为0.5 microM），竞争性和选择性抑制剂。最有趣的化合物N-[（（RS）-2-羧基-3-苯基丙酰基] -L-亮氨酸（3，KI = 0.34 microM））对脑啡肽酶的效力是ACE活性的10000倍。小鼠脑室内（icv）注射3可以增强外源性D-Ala2-Met-脑啡肽的镇痛作用，证明体内对脑啡肽酶的抑制作用。而且，单独给予icv 3可以在热板试验和扭体试验中测出小鼠的剂量依赖性镇痛作用。在以前的分析中，每只动物的ED50约为10微克，略高于硫醇。纳洛酮拮抗了所有的抗伤害感受作用，表明脑啡肽参与了镇痛作用，并

  DOI：

  10.1021/jm00355a013

文献信息

• Oral drug delivery compositions and methods
  申请人：Emisphere Technologies, Inc.

  公开号：US20030012817A1

  公开（公告）日：2003-01-16

  The present invention relates to an oral drug delivery system, and in particular to modified amino acids and modified amino acid derivatives for use as a delivery system of sensitive agents such as bioactive peptides. The modified amino acids and derivatives can form non-covalent mixtures with active biological agents and in an alternate embodiment can releasably carry active agents. Modified amino acids can also form drug containing microspheres. These mixtures are suitable for oral administration of biologically active agents to animals. Methods for the preparation of such amino acids are also disclosed.

  本发明涉及一种口服药物输送系统，具体涉及用于作为敏感剂的生物活性肽的传递系统的修饰氨基酸和修饰氨基酸衍生物。修饰氨基酸和衍生物可以与活性生物制剂形成非共价混合物，并且在另一实施例中可以释放携带活性剂。修饰氨基酸还可以形成含药微球。这些混合物适用于将生物活性剂口服给动物。还公开了制备这种氨基酸的方法。
• Neutral metalloendopeptidase inhibitors in the treatment of hypertension
  申请人：SCHERING CORPORATION

  公开号：EP0254032A2

  公开（公告）日：1988-01-27

  The method of treating hypertension with neutral metalloendopeptidase (NMEP) inhibitors, NMEP inhibitors in combination with atrial peptides, and NMEP inhibitors in combination with angiotensin converting enzyme inhibitors, as well as pharmaceutical compositions therefor, are disclosed.

  本研究公开了使用中性金属内肽酶（NMEP）抑制剂、NMEP 抑制剂与心房肽联合使用、NMEP 抑制剂与血管紧张素转换酶抑制剂联合使用治疗高血压的方法及其药物组合物。
• Oral drug compositions and methods
  申请人：Emisphere Technologies, Inc.

  公开号：EP1025840A2

  公开（公告）日：2000-08-09

  The present invention relates to an oral drug delivery system, and in particular to modified amino acids and modified amino acid derivatives for use as a delivery system of sensitive agents such as bioactive peptides. The modified amino acids and derivatives can form non-covalent mixtures with active biological agents and in an alternate embodiment can releasably carry active agents. Modified amino acids can also form durg containing microspheres. These mixtures are suitable for oral administration of biologically active agents to animals. Methods for the preparation of such amino acids are also disclosed.

  本发明涉及一种口服给药系统，特别是用作生物活性肽等敏感制剂给药系统的改性氨基酸和改性氨基酸衍生物。改性氨基酸及其衍生物可与活性生物制剂形成非共价混合物，在另一个实施方案中可释放携带活性制剂。改性氨基酸还可以形成含有微球的杜克。这些混合物适用于给动物口服生物活性剂。还公开了制备此类氨基酸的方法。
• Oral drug delivery compositions
  申请人：Emisphere Technologies, Inc.

  公开号：EP1077070A2

  公开（公告）日：2001-02-21

  The present invention relates to an oral drug delivery system, and in particular to modified amino acids and modified amino acid derivatives for use as a delivery system of sensitive agents such as bioactive peptides. The modified amino acids and derivatives can form non-covalent mixtures with active biological agents and in an alternate embodiment can releasably carry active agents. Modified amino acids can also form durg containing microspheres. These mixtures are suitable for oral administration of biologically active agents to animals. Methods for the preparation of such amino acids are also disclosed.

  本发明涉及一种口服给药系统，特别是用作生物活性肽等敏感制剂给药系统的改性氨基酸和改性氨基酸衍生物。改性氨基酸及其衍生物可与活性生物制剂形成非共价混合物，在另一个实施方案中可释放携带活性制剂。改性氨基酸还可以形成含有微球的杜克。这些混合物适用于给动物口服生物活性剂。还公开了制备此类氨基酸的方法。
• Protein particles for therapeutic and diagnostic use
  申请人：——

  公开号：US20020142046A1

  公开（公告）日：2002-10-03

  Albumin particles in the nanometer and micrometer size range in an aqueous suspension are rendered stable against resolubilization without the aid of a cross-linking agent and witout denaturation, by the incorporation of a stabilizing agent in the particle composition. Stabilizing agents disclosed include reducing agents, oxdizing agents, hydrogen-accepting molecules, high molecular weight polymers, and sulfur-containing ring compounds. Also disclosed are fibrinogen-coated particles, cross-linked or non-cross-linked, and their use as co-aggregants with platelets and with themselves for purposes of shortening bleeding time and enhancing the effect of thrombin.

  通过在颗粒组合物中加入稳定剂，可使水悬浮液中纳米和微米大小的白蛋白颗粒在不借助交联剂和不发生变性的情况下稳定地防止溶解。已公开的稳定剂包括还原剂、氧化剂、氢接受分子、高分子量聚合物和含硫环化合物。此外，还公开了交联或非交联的纤维蛋白原涂层微粒，以及它们作为与血小板和自身的共聚物的用途，以达到缩短出血时间和增强凝血酶效果的目的。